The present invention relates to a novel process for producing of 2,3-dichloro-5-(trichloromethyl)pyridine by using PCl as chlorinating agent at elevated temperature and pressure.

A composition, consisting essentially of copper, a fluoroalkyl group, and a ligand comprising at least one group-V donor. The molar ratio of copper to the fluoroalkyl group is approximately 1.

A composition, consisting essentially of copper, a fluoroalkyl group, and a ligand comprising at least one group-V donor. The molar ratio of copper to the fluoroalkyl group is approximately 1.

The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents such as pesticides or plant growth regulators.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Compounds of formula I are provided:

##STR00001##

wherein X is NH, or CH.sub.2, Y is a single bond, or —CHR.sub.5—, R.sub.1 is H, C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 hydroxyalkyl, R.sub.2 and R.sub.2′ are each independently H, C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 hydroxyalkyl, each R.sub.3 is independently H, halo, —CF.sub.3, C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 alkoxy, C.sub.3 perhaloalkyl, each R.sub.4 is independently H, halo, or C.sub.1-C.sub.4 alkyl, R.sub.5 is C.sub.1-C.sub.4 alkoxy, r is integer from 0 to 3; and p is integer from 0 to 3.

Compounds of formula I are provided:

##STR00001##

wherein X is NH, or CH.sub.2, Y is a single bond, or —CHR.sub.5—, R.sub.1 is H, C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 hydroxyalkyl, R.sub.2 and R.sub.2′ are each independently H, C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 hydroxyalkyl, each R.sub.3 is independently H, halo, —CF.sub.3, C.sub.1-C.sub.4 alkyl, or C.sub.1-C.sub.4 alkoxy, C.sub.3 perhaloalkyl, each R.sub.4 is independently H, halo, or C.sub.1-C.sub.4 alkyl, R.sub.5 is C.sub.1-C.sub.4 alkoxy, r is integer from 0 to 3; and p is integer from 0 to 3.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.

Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.

Selective potassium channel agonists and methods of use thereof are disclosed. A compound, or a pharmaceutically acceptable salt thereof, having a formula I ##STR00001##
wherein R.sup.1 is H or optionally-substituted alkyl; R.sup.2 is optionally-substituted C.sub.1-C.sub.6 alkyl or optionally-substituted cyclopropyl; R.sup.3 and R.sup.4 are each independently H or optionally-substituted alkyl; R.sup.5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R.sup.6 and R.sup.7 are each independently H, optionally-substituted alkyl, or R.sup.6 and R.sup.7 together form a carbocycle; R.sup.8 is substituted phenyl or optionally-substituted pyridinyl, provided that if R.sup.8 is substituted phenyl, then R.sup.2 is optionally-substituted cyclopropyl; and R.sup.9, R.sup.10 and R.sup.11 are each independently H, halo, or optionally-substituted alkyl.